Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Quick facts
Phase 3 pipeline
- Tyrosine kinase inhibitor · Oncology
Tyrosine kinase inhibitors block the activity of specific enzymes called tyrosine kinases, which are involved in the activation of proteins by signal transduction cascades.
Phase 2 pipeline
- Calciumfolinat · Other
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest portfolio CI brief
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest pipeline updates RSS
Frequently asked questions about Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
What is Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest's pipeline?
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest has 1 drugs in Phase 3, 1 in Phase 2, 0 in Phase 1. Late-stage candidates include Tyrosine kinase inhibitor.
Related
- Sector hub: All tracked pharma companies